Literature DB >> 31768869

Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients.

Haniye Mohammadrezakhani1,2, Behzad Baradaran1, Dariush Shanehbandi1, Milad Asadi1, Shahriar Hashemzadeh3, Khalil Hajiasgharzadeh1, Reza Safaralizadeh4.   

Abstract

PURPOSE: Long noncoding RNA (lncRNA) has been identified as an important modulator of gene expression and other activities of the cells. This kind of genes also has a significant role in the growth and development of human cancers, including colorectal cancer (CRC). Among lncRNAs, thymopoietin (TMPO)-antisense RNA 1 (TMPO-AS1) is of particular significance and might have a role in CRC regulation. The current study aimed to determine the involvement of TMPO-AS1 in CRC patients.
METHODS: In this study, 50 pairs of tumor and tumor marginal samples of CRC patients were investigated to assess the expression level of TMPO-AS1 in this cancer. For this purpose, the total RNA was isolated from the tissues using the TRIzol RNA extraction method, and after synthesis of the complementary DNA, the TMPO-AS1 expression was measured by quantitative real-time PCR (qRT-PCR) technique. In addition, clinicopathological characteristics of the CRC patients were analyzed in the study groups.
RESULTS: The findings demonstrated the overexpression of TMPO-AS1 in CRC tissues. Interestingly, the expression level of TMPO-AS1 was significantly correlated with clinicopathological features of the patients such as lymph node and distant metastasis.
CONCLUSION: The overexpression of TMPO-AS1 gene in CRC suggests that this lncRNA and its underlying signaling pathways can be considered a prognostic tumor marker and may pave the way for the future development of novel therapeutic options for CRC.

Entities:  

Keywords:  Colorectal Cancer; Long noncoding RNA; Quantitative real-time PCR; TMPO-AS1

Year:  2020        PMID: 31768869     DOI: 10.1007/s12029-019-00333-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  8 in total

1.  Downregulation of miR-7-5p Inhibits the Tumorigenesis of Esophagus Cancer via Targeting KLF4.

Authors:  Woda Shi; Jianxiang Song; Zhengya Gao; Xingchen Liu; Wencai Wang
Journal:  Onco Targets Ther       Date:  2020-09-24       Impact factor: 4.147

2.  LncRNA TMPO-AS1 Promotes Proliferation and Invasion by Sponging miR-383-5p in Glioma Cells.

Authors:  Guoyuan Liu; Haiying Yang; Lei Cao; Kun Han; Guobin Li
Journal:  Cancer Manag Res       Date:  2020-11-23       Impact factor: 3.989

3.  Inhibition of lncRNA TMPO‑AS1 suppresses proliferation, migration and invasion of colorectal cancer cells by targeting miR‑143‑3p.

Authors:  Lei Zhao; Yu Li; Ailin Song
Journal:  Mol Med Rep       Date:  2020-08-11       Impact factor: 2.952

4.  Long non-coding RNA TMPO-AS1 serves as a tumor promoter in pancreatic carcinoma by regulating miR-383-5p/SOX11.

Authors:  Feng Xue; Xin Song; Shuai Zhang; Meiwei Niu; Yu Cui; Ye Wang; Ting Zhao
Journal:  Oncol Lett       Date:  2021-02-04       Impact factor: 2.967

5.  LncRNA NEAT1/miR-204/NUAK1 Axis is a Potential Therapeutic Target for Non-Small Cell Lung Cancer.

Authors:  Ming-Ming Zhao; Lin-Yang Ge; Liang-Feng Yang; Hai-Xia Zheng; Gang Chen; Li-Zheng Wu; Shao-Ming Shi; Nan Wang; Yan-Ping Hang
Journal:  Cancer Manag Res       Date:  2020-12-29       Impact factor: 3.989

6.  Downregulation of lncRNA FGF12-AS2 suppresses the tumorigenesis of NSCLC via sponging miR-188-3p.

Authors:  Lili Zhou; Chen Xing; Dongxia Zhou; Rong Yang; Maohuai Cai
Journal:  Open Med (Wars)       Date:  2020-10-08

7.  LncRNA NEAT1 Acts as an miR-148b-3p Sponge to Regulate ROCK1 Inhibition of Retinoblastoma Growth.

Authors:  Hang Lu; Zhenjun Zhang; Yao Lu; Weiwei Xiu; Jinglin Cui
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989

8.  LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway.

Authors:  Xiaobo Guo; Yun Wang
Journal:  Cancer Med       Date:  2020-05-27       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.